Published in Gastroenterology on August 01, 2003
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer (2011) 1.76
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
The inflammatory microenvironment in colorectal neoplasia. PLoS One (2011) 1.62
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 1.29
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res (2010) 1.28
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Consumption of trans-fatty acid and its association with colorectal adenomas. Am J Epidemiol (2008) 1.06
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst (2009) 1.05
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol (2009) 1.05
An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One (2013) 1.01
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut (2005) 1.00
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer (2005) 0.96
Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96
Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95
Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer (2006) 0.95
Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol (2012) 0.94
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst (2009) 0.92
Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol (2008) 0.91
Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol (2010) 0.89
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma. Cancer Prev Res (Phila) (2012) 0.86
Surveillance in Lynch syndrome. Fam Cancer (2005) 0.85
Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc (2014) 0.85
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol (2015) 0.85
Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. Cancer Causes Control (2015) 0.84
Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84
The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer (2013) 0.82
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? ScientificWorldJournal (2012) 0.81
Nonsteroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps. Cancer Prev Res (Phila) (2011) 0.81
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol (2006) 0.81
Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role? World J Gastroenterol (2014) 0.81
Aspirin and familial adenomatous polyposis: coming full circle. Cancer Prev Res (Phila) (2011) 0.80
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila) (2011) 0.79
Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg Med Chem Lett (2015) 0.79
PPARδ and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer. Inflamm Cell Signal (2014) 0.79
The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther (2015) 0.78
Concept of chemoprevention in colorectal cancer. World J Gastrointest Oncol (2009) 0.78
COX-2 expression in adenoma: an imperfect marker for chemoprevention. Gut (2010) 0.78
Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Cancer Prev Res (Phila) (2015) 0.77
Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J Gastroenterol (2014) 0.77
NSAIDs and Colorectal Cancer Control: Promise and Challenges. Curr Pharmacol Rep (2015) 0.77
Cyclooxygenase-2 expression in the hereditary mixed polyposis syndrome. Dig Dis Sci (2005) 0.77
Pharmacological and dietary prevention for colorectal cancer. BMC Surg (2013) 0.76
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol (2015) 0.76
Associations between urinary soy isoflavonoids and two inflammatory markers in adults in the United States in 2005-2008. Cancer Causes Control (2013) 0.76
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials (2017) 0.75
Prerenal uremia induced by severe diarrhea due to colon adenoma: a case of McKittrick-Wheelock syndrome in an elderly patient. CEN Case Rep (2013) 0.75
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ (2016) 0.75
Chemoprevention in gastrointestinal physiology and disease. Targeting the progression of cancer with natural products: a focus on gastrointestinal cancer. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Chemoprevention for colorectal neoplasia. Clin Colon Rectal Surg (2008) 0.75
Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis. Curr Ther Res Clin Exp (2004) 0.75
Will an aspirin a day keep the endoscope away? Gastroenterology (2003) 0.75
Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010. Ecancermedicalscience (2011) 0.75
Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin. Drug Des Devel Ther (2013) 0.75
Response. J Natl Cancer Inst (2015) 0.75
The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol (2016) 0.75
Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals (Basel) (2010) 0.75
Targeting Platelets for the Treatment of Cancer. Cancers (Basel) (2017) 0.75
Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis. Oncotarget (2017) 0.75
Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer (2016) 0.75
Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials. Onco Targets Ther (2017) 0.75
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol (2008) 4.53
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol (2005) 4.46
Cleft lip and palate. Lancet (2009) 4.29
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet (2008) 4.04
Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy (2013) 4.03
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst (2009) 3.15
On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. Int J Epidemiol (2006) 2.66
Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int J Epidemiol (2010) 2.44
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23
DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data. Int J Epidemiol (2010) 2.23
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
A conserved mutation in an ethylene biosynthesis enzyme leads to andromonoecy in melons. Science (2008) 2.11
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res (2005) 1.92
Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc (2010) 1.91
Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol (2004) 1.91
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep (2010) 1.75
Systematic review: family history in risk assessment for common diseases. Ann Intern Med (2009) 1.70
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology (2007) 1.61
Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med (2009) 1.60
Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab (2002) 1.59
An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med (2004) 1.57
Occupational risk factors for low grade and high grade glioma: results from an international case control study of adult brain tumours. Int J Cancer (2005) 1.54
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One (2012) 1.53
Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics (2012) 1.48
Diagnostic accuracy of ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort. J Rheumatol (2011) 1.47
Addressing the challenges of cleft lip and palate research in India. Indian J Plast Surg (2009) 1.46
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. J Clin Epidemiol (2011) 1.46
Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci (2006) 1.44
[Appropiateness of colonoscopy in a gastrointestinal unit in 2001: a prospective study using criteria established by a European panel of experts]. Gastroenterol Clin Biol (2003) 1.44
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood (2007) 1.43
Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med (2007) 1.43
A network of investigator networks in human genome epidemiology. Am J Epidemiol (2005) 1.43
Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies. Int J Epidemiol (2011) 1.41
Reconstructing de novo silencing of an active plant retrotransposon. Nat Genet (2013) 1.40
Calcium supplementation for preventing colorectal cancer: where do we stand? Lancet (2004) 1.38
CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol (2003) 1.38
Changes over time in the diagnosis of rheumatoid arthritis in a 10-year cohort. J Rheumatol (2009) 1.37
Folate intake, markers of folate status and oral clefts: is the evidence converging? Int J Epidemiol (2008) 1.37
The emergence of epidemiology in the genomics age. Int J Epidemiol (2004) 1.36
A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab (2006) 1.35
Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst (2012) 1.30
Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis (2008) 1.29
A P3G generic access agreement for population genomic studies. Nat Biotechnol (2013) 1.28
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford) (2013) 1.28
Methods for meta-analyses of genome-wide association studies: critical assessment of empirical evidence. Am J Epidemiol (2012) 1.24
Understanding sickle cell carrier status identified through newborn screening: a qualitative study. Eur J Hum Genet (2009) 1.22
After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG (2009) 1.21
Pancreatic metastases: a multicentric study of 22 patients. Gastroenterol Clin Biol (2004) 1.18
Family history and improving health. Evid Rep Technol Assess (Full Rep) (2009) 1.17
A long-term high-protein diet markedly reduces adipose tissue without major side effects in Wistar male rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.17
High resolution colonoscopy with chromoscopy versus standard colonoscopy for the detection of colonic neoplasia: a randomized study. Clin Gastroenterol Hepatol (2006) 1.15
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 1.14
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther (2012) 1.13
Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev (2004) 1.11
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Features of the Arabidopsis recombination landscape resulting from the combined loss of sequence variation and DNA methylation. Proc Natl Acad Sci U S A (2012) 1.10
Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement. PLoS Med (2011) 1.09
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica (2010) 1.08
Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol (2006) 1.07
The human genome project is complete. How do we develop a handle for the pump? Am J Epidemiol (2003) 1.07
Endoscopic submucosal dissection: the best way to deal with subsquamous metaplasia? Endoscopy (2015) 1.06
The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev (2005) 1.06
Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine (2008) 1.05
Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design. Contemp Clin Trials (2006) 1.05
Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res (2004) 1.05
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs (2010) 1.05
The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A (2004) 1.04
Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Eur J Epidemiol (2011) 1.04
Temporary placement of partially covered self-expandable metal stents for anastomotic biliary strictures after liver transplantation: a prospective, multicenter study. Gastrointest Endosc (2010) 1.04
High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter (2010) 1.04
Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med (2012) 1.04
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol (2012) 1.03
Turning the pump handle: evolving methods for integrating the evidence on gene-disease association. Am J Epidemiol (2007) 1.01
Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians. J Inherit Metab Dis (2011) 1.01
Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. J Pathol (2003) 1.00
Dietary flavonoid intake and colorectal cancer: a case-control study. Br J Nutr (2009) 0.99
Recommendations and proposed guidelines for assessing the cumulative evidence on joint effects of genes and environments on cancer occurrence in humans. Int J Epidemiol (2012) 0.99
The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet (2010) 0.99
Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. Eur J Haematol (2007) 0.98
Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res (2007) 0.98
Quality indicators for colonoscopy procedures: a prospective multicentre method for endoscopy units. PLoS One (2012) 0.97
Informing parents about expanded newborn screening: influences on provider involvement. Pediatrics (2009) 0.97
Cancer risk in children and adolescents with birth defects: a population-based cohort study. PLoS One (2013) 0.96
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut (2010) 0.95
A qualitative study of provider perspectives of structural barriers to cervical cancer screening among first nations women. Womens Health Issues (2013) 0.95